ALL HRG -Experience with Modified New York Regimen

[1]  G. Heller,et al.  Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol , 1993, Cancer.

[2]  R. Gelber,et al.  Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  H. Sather,et al.  INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.

[4]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Shapiro,et al.  ABO BLOOD TYPES IN CONGENITAL HEART-DISEASE , 1975, The Lancet.

[6]  K. Krenke,et al.  Modified New York Regimen for Children with High Risk Acute Lymphoblastic Leucemia (HR-ALL). Preliminary Results , 1998 .

[7]  W. Hiddemann.  Acute Leukemias VII. Experimental Approaches and Novel Therapies. International Symposium. Munster, Germany, February 22-26, 1997. Abstracts. , 1997, Annals of hematology.

[8]  H. Sather,et al.  Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.

[9]  J. Pullen,et al.  Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.